611 results match your criteria Prostate Cancer - Neoadjuvant Androgen Deprivation


Uro-oncology in times of COVID-19: The available evidence and recommendations in the Indian scenario.

Indian J Cancer 2020 Apr-Jun;57(2):129-138

Department of Urology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.

The Corona Virus Disease-2019 (COVID-19), one of the most devastating pandemics ever, has left thousands of cancer patients to their fate. The future course of this pandemic is still an enigma, but health care services are expected to resume soon in a phased manner. This might be a long drawn process and we need to have policies in place, to be able to fight both, the SARS-CoV-2 virus and cancer, simultaneously, and emerge triumphant. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijc.IJC_356_20DOI Listing

Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic.

Eur Urol 2020 May 3. Epub 2020 May 3.

Department of Surgery, Division of Urology, Augusta University-Medical College of Georgia, Augusta, GA, USA; Georgia Cancer Center, Augusta, GA, USA. Electronic address:

Context: The coronavirus disease 2019 (COVID-19) pandemic is leading to delays in the treatment of many urologic cancers.

Objective: To provide a contemporary picture of the risks from delayed treatment for urologic cancers to assist with triage.

Evidence Acquisition: A collaborative review using literature published as of April 2, 2020. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2020.04.063DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196384PMC

Long-term Castration-related Outcomes in Patients With High-risk Localized Prostate Cancer Treated With Androgen Deprivation Therapy With or Without Docetaxel and Estramustine in the UNICANCER GETUG-12 Trial.

Clin Genitourin Cancer 2020 Apr 7. Epub 2020 Apr 7.

Department of Cancer Medicine, Institut Gustave Roussy, Villejuif, France. Electronic address:

Introduction: Neoadjuvant chemotherapy with docetaxel and estramustine (DE) significantly improved relapse-free survival in patients with high-risk localized prostate cancer treated with androgen deprivation therapy (ADT) for 3 years and a local treatment in the GETUG-12 phase III trial. We sought to explore whether the addition of DE impacts long-term treatment-related side effects.

Patients And Methods: Patients randomized within the UNICANCER GETUG-12 trial at Gustave Roussy who were alive when ADT was discontinued were followed-up prospectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2020.03.017DOI Listing

The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial.

Eur Urol 2020 Apr 6. Epub 2020 Apr 6.

Carolina Urologic Research Center, Myrtle Beach, SC, USA.

Background: External beam radiotherapy (EBRT) with neoadjuvant/adjuvant androgen deprivation therapy (ADT) is an established treatment option to prolong survival for patients with intermediate- and high-risk prostate cancer (PCa). Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, was evaluated in this clinical setting in comparison with degarelix, an injectable GnRH antagonist.

Objective: To evaluate the safety and efficacy of relugolix to achieve and maintain castration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2020.03.001DOI Listing

Stereotactic Body Radiotherapy Using CyberKnife® for Localized Low- and Intermediate-risk Prostate Cancer: Initial Report on a Phase I/II Trial.

Anticancer Res 2020 Apr;40(4):2053-2057

Department of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, Japan.

Background: The present study aimed to evaluate the toxicity and efficacy of stereotactic body radiotherapy (SBRT) for localized prostate cancer.

Patients And Methods: We investigated 25 patients treated with SBRT of 35 Gy per five fractions from May 2014 to March 2015.

Results: The median age of patients was 70 years, four (16%) patients were low risk and 21 (84%) were intermediate risk. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14162DOI Listing

PSMA-PET/CT-avid metastatic prostate cancer to the penis.

BMJ Case Rep 2020 Mar 24;13(3). Epub 2020 Mar 24.

Urology, Princess Alexandra Hospital Health Service District, Woolloongabba, Queensland, Australia.

Penile metastases from prostate cancer (PC) are rarely reported in the literature. Most commonly diagnosed due to presentation with malignant priapism and other urinary symptoms or from findings on clinical examination, prognosis has been reported to be poor. The authors outline a case of penile metastasis from advanced PC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2019-233522DOI Listing

T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer.

Clin Cancer Res 2020 Mar 15. Epub 2020 Mar 15.

Columbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, New York.

Purpose: Previous studies suggest that androgen deprivation therapy (ADT) promotes antitumor immunity in prostate cancer. Whether a vaccine-based approach can augment this effect remains unknown.

Patients And Methods: We conducted a neoadjuvant, randomized study to quantify the immunologic effects of a GM-CSF-secreting allogeneic cellular vaccine in combination with low-dose cyclophosphamide (Cy/GVAX) followed by degarelix versus degarelix alone in patients with high-risk localized prostate adenocarcinoma who were planned for radical prostatectomy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-19-3372DOI Listing

Neoadjuvant Leuprolide Therapy with Radical Prostatectomy: Long-term Effects on Health-related Quality of Life.

Eur Urol Focus 2020 Mar 9. Epub 2020 Mar 9.

Department of Urology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA, USA. Electronic address:

Background: Neoadjuvant androgen ablation (neoadjuvant androgen deprivation therapy [NADT]) is used prior to radical prostatectomy, contrary to guidelines, but its long-term effects on quality of life is unknown.

Objective: To determine the effect of NADT on patient's long-term recovery following surgery.

Design, Setting, And Participants: From March 2011 to August 2013, 5808 men with newly diagnosed prostate were followed up to 24 mo. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euf.2020.03.001DOI Listing

Recovery of serum testosterone following neoadjuvant androgen deprivation therapy in Japanese prostate cancer patients treated with low-dose rate brachytherapy.

Aging Male 2020 Feb 25:1-7. Epub 2020 Feb 25.

Department of Integrative Cancer Therapy and Urology, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.

To investigate the time course of total testosterone (TT) recovery after cessation of androgen deprivation therapy (ADT) in Japanese patients treated with brachytherapy. In total, 125 patients with prostate cancer received 6 months of neoadjuvant ADT (nADT) followed by low-dose rate (LDR) brachytherapy. TT was measured every 3 months after cessation of nADT, and some predictive factors affecting TT recovery were analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13685538.2020.1731450DOI Listing
February 2020

A case report of multiple primary prostate tumors with differential drug sensitivity.

Nat Commun 2020 02 13;11(1):837. Epub 2020 Feb 13.

Laboratory of Genitourinary Cancer Pathogenesis, National Cancer Institute, NIH, 37 Convent Drive, Bethesda, MD, 20892, USA.

Localized prostate cancers are genetically variable and frequently multifocal, comprising spatially distinct regions with multiple independently-evolving clones. To date there is no understanding of whether this variability can influence management decisions for patients with prostate tumors. Here, we present a single case from a clinical trial of neoadjuvant intense androgen deprivation therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-020-14657-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7018822PMC
February 2020

PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer.

Signal Transduct Target Ther 2020 31;5. Epub 2020 Jan 31.

1Molecular Diagnostics and Therapeutics Group, University College London, London, UK.

PIM kinases have been shown to play a role in prostate cancer development and progression, as well as in some of the hallmarks of cancer, especially proliferation and apoptosis. Their upregulation in prostate cancer has been correlated with decreased patient overall survival and therapy resistance. Initial efforts to inhibit PIM with monotherapies have been hampered by compensatory upregulation of other pathways and drug toxicity, and as such, it has been suggested that co-targeting PIM with other treatment approaches may permit lower doses and be a more viable option in the clinic. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41392-020-0109-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6992635PMC
January 2020

Neoadjuvant Approaches Prior To Radical Prostatectomy.

Cancer J 2020 Jan/Feb;26(1):2-12

University of California, San Diego, San Diego, CA.

Patients with high-risk localized prostate cancer benefit from multimodality therapy of curative intent. Androgen-deprivation therapy (ADT) combined with radiation improves survival in this population. However, prior clinical trials of neoadjuvant ADT and surgery failed to consistently demonstrate a survival advantage. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0000000000000424DOI Listing
January 2020

The effect of anaemia on normal tissue toxicity and survival outcomes in prostate cancer treated with radical radiotherapy and neo-adjuvant androgen deprivation.

Br J Radiol 2020 Apr 29;93(1108):20190577. Epub 2020 Jan 29.

Cancer Trials Ireland (formally All-Ireland Cooperative Oncology Research Group, ICORG), Dublin, Ireland.

Objective: It has been established that survival and toxicity outcomes in some cancer types could be influenced by haemoglobin (Hb) levels. This study aims to determine if pre-treatment Hb is associated with late toxicity or survival outcomes in prostate cancer.

Methods: Data from one Phase III randomised controlled trial and one single arm translational trial were analysed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1259/bjr.20190577DOI Listing

Multiparametric MRI as a Biomarker of Response to Neoadjuvant Therapy for Localized Prostate Cancer-A Pilot Study.

Acad Radiol 2019 Dec 17. Epub 2019 Dec 17.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Rationale And Objectives: To explore a role for multiparametric MRI (mpMRI) as a biomarker of response to neoadjuvant androgen deprivation therapy (ADT) for prostate cancer (PCa).

Materials And Methods: This prospective study was approved by the institutional review board and was HIPAA compliant. Eight patients with localized PCa had a baseline mpMRI, repeated after 6-months of ADT, followed by prostatectomy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.acra.2019.10.017DOI Listing
December 2019

Response of intraductal carcinoma of the prostate to androgen deprivation therapy predicts prostate cancer prognosis in radical prostatectomy patients.

Prostate 2020 02 20;80(3):284-290. Epub 2019 Dec 20.

Department of Surgical Pathology, Aichi Medical University, Nagakute, Aichi, Japan.

Background: Intraductal carcinoma of the prostate (IDC-P) has a poor prognosis and is thought to be completely resistant to current therapies, including androgen deprivation therapy (ADT). However, to date, there are no data showing direct evidence of such resistance.

Methods: We retrospectively evaluated 145 patients with high-risk prostate cancer who underwent radical prostatectomy (RP) with neoadjuvant ADT between 1991 and 2005. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.23942DOI Listing
February 2020

Sequencing of Androgen-Deprivation Therapy With External-Beam Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial.

J Clin Oncol 2020 Feb 12;38(6):593-601. Epub 2019 Dec 12.

The Ottawa Hospital Regional Cancer Center, Ottawa, Ontario, Canada.

Purpose: Dose-escalated radiotherapy (RT) with androgen-deprivation therapy (ADT) is a standard definitive treatment of localized prostate cancer (LPCa). The optimal sequencing of these therapies is unclear. Our phase III trial compared neoadjuvant versus concurrent initiation of ADT in combination with dose-escalated prostate RT (PRT). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.19.01904DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186584PMC
February 2020

Low incidence of late recurrence in patients with intermediate-risk prostate cancer treated by intensity-modulated radiation therapy plus short-term androgen deprivation therapy.

Int J Clin Oncol 2020 Apr 9;25(4):713-719. Epub 2019 Dec 9.

Department of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.

Objectives: This study evaluated the long-term outcomes of intensity-modulated radiation therapy (IMRT) combined with short-term neoadjuvant androgen deprivation therapy (ADT) in patients with intermediate-risk (IR) prostate cancer (PCa).

Materials And Methods: Patients with IR PCa treated with IMRT at our institution between September 2000 and November 2010 were analyzed retrospectively. The treatment consisted of IMRT (70-78 Gy in 35-39 fractions) combined with 6 months of neoadjuvant ADT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10147-019-01596-7DOI Listing

Achieving PSA < 0.2 ng/ml before Radiation Therapy Is a Strong Predictor of Treatment Success in Patients with High-Risk Locally Advanced Prostate Cancer.

Prostate Cancer 2019 17;2019:4050352. Epub 2019 Oct 17.

Division of Urology, Department of Molecular Oncology, Niigata University Graduate School of Medical and Dental Sciences, 1-757, Asahimachi-dori, Chuo-ku, Niigata 951-8510, Japan.

Background: To predict long-term treatment outcome of radiation therapy (RT) plus androgen deprivation therapy (ADT) for high-risk locally advanced prostate cancer.

Methods: In total, 204 patients with the National Comprehensive Cancer Network (NCCN) high risk locally advanced prostate cancer (PSA > 20 ng/ml, Gleason score ≧ 8, clinical T stage ≧ 3a) were treated with definitive RT with ADT. Median follow up period was 113 months (IQR: 95-128). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/4050352DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6854218PMC
October 2019

The effect of androgen deprivation therapy on Ga-PSMA tracer uptake in non-metastatic prostate cancer patients.

Eur J Nucl Med Mol Imaging 2020 Mar 15;47(3):632-641. Epub 2019 Nov 15.

Adana Dr. Turgut Noyan Research and Treatment Center, Department of Nuclear Medicine, Başkent University Faculty of Medicine, Adana, Turkey.

Purpose: To evaluate the effect of neoadjuvant androgen deprivation treatment (ADT) on prostate-specific membrane antigen (PSMA) tracer uptake demonstrated in Ga-PSMA-positron emission tomography (PET/CT) in non-metastatic hormone-naïve prostate cancer (PC) patients.

Materials And Methods: The clinical data of 108 PC patients who received neoadjuvant ADT were retrospectively analyzed. All patients had a baseline Ga-PSMA-PET/CT scan, and a second scan was delivered median of 2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-04581-4DOI Listing

Radical cytoreductive prostatectomy in men with prostate cancer and oligometastatic disease.

Curr Opin Urol 2020 Jan;30(1):90-97

Department of Urology, Uro-Oncology, Robot-Assisted and Reconstructive Urology, University of Cologne, Cologne, Germany.

Purpose Of Review: Local treatment of the primary by either radical prostatectomy or radiation therapy is discussed controversially. The role of cytoreductive radical prostatectomy has been evaluated in few retrospective clinical studies but data of prospective randomized clinical phase-III trials are lacking. It is the purpose of this review to reflect the current knowledge on indication, functional and oncological outcomes of cytoreductive radical prostatectomy to objectively highlight what can be expected from this approach. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOU.0000000000000691DOI Listing
January 2020
28 Reads

Ten-Year Treatment Outcomes of Radical Prostatectomy Vs External Beam Radiation Therapy Vs Brachytherapy for 1503 Patients With Intermediate-risk Prostate Cancer.

Urology 2020 02 5;136:180-189. Epub 2019 Nov 5.

Department of Radiation Oncology, Kaiser Permanente, Los Angeles Medical Center, Los Angeles, CA.

Objective: To compare 10-year oncologic treatment outcomes of radical prostatectomy (RP) vs external beam radiation therapy (EBRT) vs brachytherapy (BT) for patients with intermediate-risk prostate cancer (IRPC).

Methods: A retrospective analysis using propensity score matching was performed on 1503 IRPC patients who underwent treatment from 2004 to 2007. Eight hundred and nineteen underwent RP, 574 underwent EBRT to a median dose of 75. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2019.09.040DOI Listing
February 2020

Oncological outcome of neoadjuvant low-dose estramustine plus LHRH agonist/antagonist followed by extended radical prostatectomy for Japanese patients with high-risk localized prostate cancer: a prospective single-arm study.

Jpn J Clin Oncol 2020 Jan;50(1):66-72

Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.

Background: Patients with advanced high-risk prostate cancer (PCa) are prone to have worse pathological diagnoses of positive surgical margins and/or lymph node invasion, resulting in early biochemical recurrence (BCR) despite having undergone radical prostatectomy (RP). Therefore, it is controversial whether patients with high-risk PCa should undergo RP. The purpose of this study was to evaluate the efficacy of neoadjuvant chemohormonal therapy (NAC) followed by "extended" RP. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyz138DOI Listing
January 2020
1 Read

Prognostic significance of castrate testosterone levels for patients with intermediate and high risk prostate cancer.

World J Clin Oncol 2019 Aug;10(8):283-292

Department of Radiation Oncology, Hacettepe University Faculty of Medicine, Ankara 06100, Turkey M.D.

Background: Testosterone level of < 50 ng/dL has been used to define castrate level after surgery or after androgen deprivation treatment (ADT) in metastatic prostate cancer (PC).

Aim: To evaluate the effect of two different castrate testosterone levels, < 50 and < 20 ng/dL, on biochemical relapse free survival (BRFS) in patients with non-metastatic intermediate and high risk PC receiving definitive radiotherapy (RT) and ADT.

Methods: Between April 1998 and February 2011; 173 patients with intermediate and high risk disease were treated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5306/wjco.v10.i8.283DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717705PMC
August 2019
4 Reads

Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: A retrospective comparative study.

Urol Oncol 2019 12 27;37(12):991-998. Epub 2019 Aug 27.

Department of Urology, Renji Hospital Affiliated to Shanghai Jiao Tong University, School of Medicine, Shanghai, China. Electronic address:

Objective: Docetaxel has been shown to be an effective chemotherapy agent when combined with androgen deprivation therapy for hormone sensitive metastatic prostate cancer (CaP). Since very high risk CaP has a high rate of occult metastatic disease and early recurrence, we hypothesize that patients with very high risk locally advanced CaP may benefit from docetaxel-based neoadjuvant chemohormonal therapy (NCHT). Thus, we conducted a retrospective study to identify the outcome of these patients treated with NCHT followed by radical prostatectomy (RP). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2019.07.009DOI Listing
December 2019
2 Reads

Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer-Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial.

Eur Urol 2019 Dec 20;76(6):823-830. Epub 2019 Aug 20.

Karlstad Central Hospital, Karlstad, Sweden.

Background: Docetaxel combined with androgen deprivation therapy (ADT) has improved patient survival for advanced prostate cancer (PCa).

Objective: This randomised trial aimed to evaluate whether six courses of docetaxel improved biochemical disease-free survival (BDFS) after radical radiotherapy (RT) for intermediate- or high-risk PCa patients.

Design, Setting, And Participants: A total of 376 patients were randomised in this multinational phase III study, and received either six cycles of adjuvant docetaxel 75 mg/m every 3 wk without continuous prednisone (arm A, n = 188) or surveillance (arm B, n = 188) after RT (NTC006653848). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2019.08.010DOI Listing
December 2019
5 Reads

Association between Radical Prostatectomy and Survival in Men with Clinically Node-positive Prostate Cancer.

Eur Urol Oncol 2019 09 19;2(5):584-588. Epub 2018 Oct 19.

Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, USA. Electronic address:

Evidence supporting radical prostatectomy (RP) for men with clinically node-positive (cN+) prostate cancer (PC) is limited. In a US national database, we identified 741 men with cN+ nonmetastatic PC diagnosed during 2000-2015 who underwent definitive local therapy with RP (n=78), radiotherapy (RT) with neoadjuvant androgen deprivation therapy (ADT) (n=193), or nondefinitive therapy with ADT alone (n=445) or observation (n=25). We compared PC-specific mortality (PCSM) and all-cause mortality (ACM) using multivariable Fine-Gray competing risk regression and Cox regression, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euo.2018.09.015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6697241PMC
September 2019
2 Reads

Extended lymphadenectomy for high-risk prostate cancer in patients with chronic lymphocytic leukemia may not be necessary: a report of two cases.

BMC Cancer 2019 Jul 9;19(1):676. Epub 2019 Jul 9.

Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 1630 Dongfang Road, Pudong District, Shanghai, 200127, People's Republic of China.

Background: Chronic lymphocytic leukemia is a malignancy with good prognosis. However, the incidence of secondary tumors increases every year after the diagnosis of chronic lymphotcytic leukemia. One of the induced secondary tumors is prostate cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-019-5876-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617590PMC
July 2019
5 Reads

Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report.

BMC Cancer 2019 Jun 11;19(1):562. Epub 2019 Jun 11.

Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.

Background: Cabazitaxel (CBZ) chemotherapy for metastatic castration-resistant prostate cancer (mCRPC) is believed to be palliative because the radiological response rate is low and a durable response is rare. Here, we describe a rare case of a patient with mCRPC who was treated with CBZ chemotherapy and showed a durable radiological response and a complete biochemical response.

Case Presentation: A 43-year-old man with prostate cancer and metastasis of the pubic bone underwent neoadjuvant androgen deprivation and docetaxel therapy, followed by laparoscopic prostatectomy, extended lymphadenectomy, and metastatectomy in 2014. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-019-5782-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558884PMC
June 2019
5 Reads

Early biochemical predictors of survival in intermediate and high-risk prostate cancer treated with radiation and androgen deprivation therapy.

Radiother Oncol 2019 11 6;140:34-40. Epub 2019 Jun 6.

Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, USA. Electronic address:

Background And Purpose: To identify early biochemical predictors of survival in intermediate- and high-risk prostate cancer patients with a pre-treatment PSA <20 ng/mL following definitive radiation therapy (RT) and androgen deprivation therapy (ADT).

Materials And Methods: A single-institution review of 2566 intermediate and high-risk prostate cancer patients treated with definitive RT and neoadjuvant and concurrent ADT from 1990 to 2012 was performed. The first prostate-specific antigen (PSA) value within three months of ADT initiation (post-ADT PSA) and the first PSA within three months after RT completion (post-RT PSA) were recorded. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.radonc.2019.04.003DOI Listing
November 2019
7 Reads

Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone.

Eur Urol 2019 Oct 6;76(4):418-424. Epub 2019 Jun 6.

Department of Genitourinary Medical Oncology, David H. Koch Center for Applied Research of GU Cancers, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Optimal therapeutic strategy remains an unmet need in localised high-risk prostate cancer (LHRPC). Androgen biosynthesis inhibition in the preoperative setting may improve outcomes. In this single-centre randomised trial, we looked at therapy outcomes of preoperative treatment with abiraterone acetate+prednisone (AAP)+luteinising hormone-releasing hormone agonist (LHRHa) or LHRHa alone followed by radical prostatectomy in 65 men. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2019.05.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7205516PMC
October 2019
10 Reads

Ten-year outcomes of high-dose intensity-modulated radiation therapy for nonmetastatic prostate cancer with unfavorable risk: early initiation of salvage therapy may replace long-term adjuvant androgen deprivation.

Int J Clin Oncol 2019 Oct 31;24(10):1247-1255. Epub 2019 May 31.

Department of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.

Background: The optimal timing of salvage androgen deprivation therapy (ADT) following definitive radiation therapy for prostate cancer (PCa) is unknown. This study evaluated the efficacy of early initiation of salvage-ADT (S-ADT) based on predetermined timing among patients with unfavorable PCa treated with high-dose intensity-modulated radiation therapy (IMRT).

Materials And Methods: High-risk (HR) and very-high-risk (VHR) PCa patients treated with IMRT at our institution between September 2000 and December 2010 were analyzed retrospectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10147-019-01478-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6736780PMC
October 2019
5 Reads

Treatment outcomes of prostate cancer patients with Gleason score 8-10 treated with definitive radiotherapy : TROD 09-001 multi-institutional study.

Strahlenther Onkol 2019 Oct 29;195(10):882-893. Epub 2019 May 29.

Department of Radiation Oncology, Hacettepe University, Faculty of Medicine, 06100, Ankara, Turkey.

Purpose: To validate the clinical outcomes and prognostic factors in prostate cancer (PCa) patients with Gleason score (GS) 8-10 disease treated with external beam radiotherapy (EBRT) + androgen deprivation therapy (ADT) in the modern era.

Methods: Institutional databases of biopsy proven 641 patients with GS 8-10 PCa treated between 2000 and 2015 were collected from 11 institutions. In this multi-institutional Turkish Radiation Oncology Group study, a standard database sheet was sent to each institution for patient enrollment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00066-019-01476-zDOI Listing
October 2019
5 Reads

Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases.

Eur Urol Oncol 2018 05 15;1(1):46-53. Epub 2018 May 15.

Department of Urology, Mayo Clinic, Rochester, MN, USA.

Background: Androgen deprivation therapy (ADT) represents the standard treatment for hormone-naïve prostate cancer with systemic metastases (mPCA). The role of radical prostatectomy (RP) in this setting is unclear.

Objective: To evaluate the oncological and functional outcomes of men with mPCA who underwent cytoreductive RP (CRP). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euo.2018.03.002DOI Listing
May 2018
12 Reads

Early Tolerance Outcomes of Stereotactic Hypofractionated Accelerated Radiation Therapy Concomitant with Pelvic Node Irradiation in High-risk Prostate Cancer.

Adv Radiat Oncol 2019 Apr-Jun;4(2):337-344. Epub 2019 Jan 31.

Departments of Radiation Oncology and Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York.

Purpose: This study aimed to evaluate the toxicity of prostate and pelvic lymph node stereotactic body radiation therapy (SBRT) for high-risk prostate cancer.

Methods And Materials: Twenty-three patients with high-risk or lymph node-positive prostate cancer were treated with SBRT that delivered 37.5 to 40 Gy in 5 fractions to the prostate and seminal vesicles, with concomitant treatment of the pelvic nodes to 25 Gy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.adro.2018.12.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6460324PMC
January 2019
7 Reads

mpMRI preoperative staging in men treated with antiandrogen and androgen deprivation therapy before robotic prostatectomy.

Urol Oncol 2019 06 15;37(6):352.e25-352.e30. Epub 2019 Apr 15.

Laboratory for Genitourinary Cancer Pathogenesis, National Cancer Institute, National Institutes of Health, Bethesda, MD. Electronic address:

Introduction: Using multiparametric magnetic resonance imaging (mpMRI), we sought to preoperatively characterize prostate cancer (PCa) in the setting of antiandrogen plus androgen deprivation therapy (AA-ADT) prior to robotic-assisted radical prostatectomy (RARP). We present our preliminary findings regarding mpMRI depiction of changes of disease staging features and lesion appearance in treated prostate.

Methods: Prior to RARP, men received 6 months of enzalutamide and goserelin. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10781439193001
Publisher Site
http://dx.doi.org/10.1016/j.urolonc.2019.01.012DOI Listing
June 2019
39 Reads

Association of prostate cancer SLCO gene expression with Gleason grade and alterations following androgen deprivation therapy.

Prostate Cancer Prostatic Dis 2019 12 19;22(4):560-568. Epub 2019 Mar 19.

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Background: SLCO-encoded transporters have been associated with progression to castration-resistant prostate cancer (CRPC) after initiation of androgen deprivation therapy (ADT). Although expressed at lower levels than in CRPC tissues, SLCO-encoded transporters may also play a role in response of primary prostate cancer (PCa) to ADT and biochemical recurrence.

Methods: We systematically explored expression of the 11 human SLCO genes in a large sample of untreated and ADT-treated normal prostate (NP) and primary PCa tissues, including tumors treated with neoadjuvant abiraterone. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41391-019-0141-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6752995PMC
December 2019
3 Reads

Improved survival for patients with prostate cancer receiving high-dose-rate brachytherapy boost to EBRT compared with EBRT alone.

Brachytherapy 2019 May - Jun;18(3):313-321. Epub 2019 Mar 4.

Alfred Health Radiation Oncology, Alfred Hospital, Melbourne, Victoria, Australia; Department of Surgery, Central Clinical School, Monash University, The Alfred Centre, Melbourne, Victoria, Australia. Electronic address:

Purpose: High-dose-rate (HDR) brachytherapy boost is a treatment of intermediate- to high-risk prostate cancer, but long-term clinical outcome data are sparse. We report long-term survival and toxicity data in a cohort of patients treated in a single institution.

Methods: Between 1998 and 2004, 654 patients with localized prostate cancer received either 3-dimensional conformal radiotherapy (median 46 Gy) with an HDR (median 18 Gy in three fractions) boost ("3-D conformal radiotherapy [3DCRT] + HDR"; 215 patients) or 3DCRT alone ("3DCRT"; median 70 Gy; 439 patients) with curative intent. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brachy.2019.01.013DOI Listing
December 2019
5 Reads

Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone.

J Clin Oncol 2019 04 27;37(11):923-931. Epub 2019 Feb 27.

2 Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA.

Purpose: Patients with locally advanced prostate cancer have an increased risk of cancer recurrence and mortality. In this phase II trial, we evaluate neoadjuvant enzalutamide and leuprolide (EL) with or without abiraterone and prednisone (ELAP) before radical prostatectomy (RP) in men with locally advanced prostate cancer.

Patients And Methods: Eligible patients had a biopsy Gleason score of 4 + 3 = 7 or greater, prostate-specific antigen (PSA) greater than 20 ng/mL, or T3 disease (by prostate magnetic resonance imaging). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.18.01777DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7051849PMC
April 2019
10 Reads

Five-Year Outcomes of a Phase 1 Dose-Escalation Study Using Stereotactic Body Radiosurgery for Patients With Low-Risk and Intermediate-Risk Prostate Cancer.

Int J Radiat Oncol Biol Phys 2019 05 4;104(1):42-49. Epub 2019 Jan 4.

Department of Radiation Medicine, Northwell Health, Lenox Hill Hospital, New York, New York.

Purpose: To report toxicity outcomes, prostate-specific antigen (PSA) relapse, and cumulative incidence posttreatment biopsy results among patients treated on a prospective dose escalation study using ultra-hypofractionated stereotactic body radiation therapy (SBRT) for patients with low- and intermediate-risk prostate cancer.

Methods And Materials: A total of 136 patients were enrolled in a phase 1 dose-escalation study to determine the tolerance of escalating radiation dose levels of SBRT for the treatment of localized prostate cancer. The initial dose level was 32. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2018.12.045DOI Listing
May 2019
45 Reads

Changes in lower urinary tract symptoms after iodine-125 brachytherapy for prostate cancer.

Clin Transl Radiat Oncol 2019 Jan 17;14:51-58. Epub 2018 Nov 17.

Department of Urology, Nara Medical University, Japan.

Purpose: To investigate chronological changes in lower urinary tract symptoms (LUTS) in patients who received iodine-125 brachytherapy (BT) for prostate cancer.

Methods: We enrolled 706 patients who received BT. Of these, 265 (38%) received BT combined with external beam radiation therapy (EBRT). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S24056308183005
Publisher Site
http://dx.doi.org/10.1016/j.ctro.2018.11.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282112PMC
January 2019
41 Reads

Impact of androgen deprivation therapy on apparent diffusion coefficient and T2w MRI for histogram and texture analysis with respect to focal radiotherapy of prostate cancer.

Strahlenther Onkol 2019 May 26;195(5):402-411. Epub 2018 Nov 26.

Christian Doppler Laboratory for Medical Radiation Research for Radiation Oncology, Medical University of Vienna, Vienna, Austria.

Purpose: Accurate prostate cancer (PCa) detection is essential for planning focal external beam radiotherapy (EBRT). While biparametric MRI (bpMRI) including T2-weighted (T2w) and diffusion-weighted images (DWI) is an accurate tool to localize PCa, its value is less clear in the case of additional androgen deprivation therapy (ADT). The aim of this study was to investigate the value of a textural feature (TF) approach on bpMRI analysis in prostate cancer patients with and without neoadjuvant ADT with respect to future dose-painting applications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00066-018-1402-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488548PMC
May 2019
7 Reads

Clinical outcome of high dose rate brachytherapy with external beam radiotherapy for high-risk prostate cancer: a single institutional retrospective study.

Jpn J Clin Oncol 2019 Jan;49(1):87-91

Department of Radiation Oncology, Saitama Medical University International Medical Center, Saitama, Japan.

Objectives: : This study investigated the clinical outcome of neoadjuvant androgen deprivation therapy followed by high dose rate brachytherapy (HDR-BT, called NEH) with external beam radiotherapy (EBRT) in high-risk prostate cancer (PCa) patients in our institution. : From 2007 to 2012, 192 high-risk PCa patients underwent neoadjuvant treatment-EBRT-NEH ( n = 192). Relations between clinical factors (prostate-specific antigen; PSA, cT stage, Gleason score) and biochemical recurrence were retrospectively analyzed. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/jjco/advance-article/doi/10.1093/jj
Publisher Site
http://dx.doi.org/10.1093/jjco/hyy174DOI Listing
January 2019
19 Reads

Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status.

Ann Surg Oncol 2019 Jan 14;26(1):297-305. Epub 2018 Nov 14.

Dana-Farber/Brigham and Women's Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.

Purpose: In this study, we sought to describe the contemporary trends in utilization of neoadjuvant androgen deprivation therapy (ADT). As a secondary endpoint, we assessed the community-level effect of neoadjuvant ADT on positive surgical margins after radical prostatectomy (RP).

Methods: Using the National Cancer Database (2004-2014), we identified patients with clinically localized prostate cancer (PCa) [cT1-4N0M0] treated with RP. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1245/s10434-018-7035-z
Publisher Site
http://dx.doi.org/10.1245/s10434-018-7035-zDOI Listing
January 2019
56 Reads

Measuring testosterone and testosterone replacement therapy in men receiving androgen deprivation therapy for prostate cancer: A survey of UK uro-oncologists' opinions and practice.

Int J Clin Pract 2019 Sep 4;73(9):1-6. Epub 2018 Dec 4.

Division of Cancer and Genetics, School of Medicine, Cardiff University and Velindre Cancer Centre, Cardiff, UK.

Aim: To explore the practice and attitudes of uro-oncologists in the UK regarding monitoring testosterone levels and the use of testosterone replacement therapy (TRT) in their prostate cancer patients treated with androgen deprivation therapy (ADT).

Methods: An expert-devised online questionnaire was completed by the members of the British Uro-oncology Group (BUG).

Results: Of 160 uro-oncologists invited, 84 completed the questionnaire. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijcp.13292DOI Listing
September 2019
21 Reads

Which Patients with Clinically Node-positive Prostate Cancer Should Be Considered for Radical Prostatectomy as Part of Multimodal Treatment? The Impact of Nodal Burden on Long-term Outcomes.

Eur Urol 2019 05 5;75(5):817-825. Epub 2018 Nov 5.

Unit of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy.

Background: A role for local therapies including radical prostatectomy (RP) in prostate cancer (PCa) patients with clinical lymphadenopathies has been proposed. However, no data are available to identify men who would benefit from RP in this setting.

Objective: To identify predictors of clinical recurrence (CR) in surgically managed PCa patients with clinical lymphadenopathies. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03022838183083
Publisher Site
http://dx.doi.org/10.1016/j.eururo.2018.10.042DOI Listing
May 2019
35 Reads

The addition of chemotherapy in the definitive management of high risk prostate cancer.

Urol Oncol 2018 11 9;36(11):475-487. Epub 2018 Oct 9.

Department of Radiation Oncology, Winship Cancer Institute at Emory University, Atlanta, GA; Winship Cancer Institute at Emory University, Atlanta, GA.

In attempt to improve long-term disease control outcomes for high-risk prostate cancer, numerous clinical trials have tested the addition of chemotherapy (CTX)-either adjuvant or neoadjuvant-to definitive local therapy, either radical prostatectomy (RP) or radiation therapy (RT). Neoadjuvant trials generally confirm safety, feasibility, and pre-RP PSA reduction, but rates of pathologic complete response are rare, and no indications for neoadjuvant CTX have been firmly established. Adjuvant regimens have included CTX alone or in combination with androgen deprivation therapy (ADT). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2018.07.020DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214780PMC
November 2018
8 Reads

Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer.

Eur Urol 2019 01 2;75(1):44-60. Epub 2018 Oct 2.

Institut Gustave Roussy, University of Paris Sud, Villejuif, France.

Context: Systemic therapies, combined with local treatment for high-risk prostate cancer, are recommended by the international guidelines for specific subgroups of patients; however, for many of the clinical scenarios, it remains a research field.

Objective: To perform a systematic review, and describe current evidence and perspectives about the multimodal treatment of high-risk prostate cancer.

Evidence Acquisition: We performed a systematic review of PubMED, Embase, Cochrane Library, European Society of Medical Oncology/American Society of Clinical Oncology Annual proceedings, and clinicalTrial. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03022838183054
Publisher Site
http://dx.doi.org/10.1016/j.eururo.2018.07.027DOI Listing
January 2019
19 Reads

Late biochemical recurrence after radical prostatectomy is associated with a slower rate of progression.

BJU Int 2019 06 19;123(6):976-984. Epub 2018 Oct 19.

Departments of Urology and Surgery, Royal Melbourne Hospital, The University of Melbourne, Parkville, Victoria,, Australia.

Objective: To characterise the pattern of late biochemical recurrence (BCR) in the largest contemporary cohort of patients with localised prostate cancer treated with radical prostatectomy (RP) in the active surveillance era.

Patients And Methods: Consecutive patients who underwent RP for localised prostate cancer between 2003 and 2017 were identified from a prospectively recorded, dedicated prostate cancer database. Patients who received neoadjuvant androgen-deprivation therapy were excluded. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bju.14556DOI Listing
June 2019
6 Reads

Adherence to hormonal deprivation therapy in prostate cancer in clinical practice: a retrospective, single-center study.

Minerva Urol Nefrol 2019 Apr 19;71(2):181-184. Epub 2018 Sep 19.

Department of Urology, ASL Abruzzo 2, Chieti, Italy.

Background: Androgen-deprivation therapy is one of the options available for treating both advanced and metastatic prostate cancer (PCa). It is used as an adjuvant or neoadjuvant therapy, either alone or in combination with radiotherapy (RT) or surgery. The aim of this study was to appraise adherence to androgen-deprivation therapy (ADT). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.23736/S0393-2249.18.03109-0DOI Listing
April 2019
27 Reads

Practice patterns of primary EBRT with and without ADT in prostate cancer treatment.

Prostate Cancer Prostatic Dis 2019 03 31;22(1):117-124. Epub 2018 Aug 31.

University of California, San Francisco CA, USA.

Background: Androgen deprivation therapy (ADT) has been shown to improve survival for men with intermediate and high-risk prostate cancer undergoing external-beam radiation therapy (EBRT). Using data from a community-based prospective disease registry, we investigated usage of EBRT with or without neoadjuvant ADT.

Methods: The CaPSURE database contains 14,863 men with prostate cancer, including 1337 men diagnosed between 1990 and 2014 with localized disease who received EBRT as primary treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41391-018-0084-3DOI Listing
March 2019
26 Reads